Effects of Age on Outcome in the SENTIS Trial: Better Outcomes in Elderly PatientsLeker R.R.a · Molina C.b · Cockroft K.c · Liebeskind D.S.d · Concha M.f · Shuaib A.i · De Deyn P.P.j · Burgin W.S.g · Gupta R.h · Dillon W.e · Diener H.-C.k
aHadassah-Hebrew University Medical Center, Jerusalem, Israel; bVall d´Hebron University Hospital, Barcelona, Spain; cPenn State Hershey Medical Center, Hershey, Pa., dUniversity of California Los Angeles, Los Angeles, Calif., eUniversity of California San Francisco, San Francisco, Calif., fSarasota Memorial Hospital, Sarasota, Fla., gUniversity of South Florida, Tampa, Fla., and hEmory University, Atlanta, Ga., USA; iUniversity of Alberta, Edmonton, Alta., Canada; jZNA Middelheim, Antwerpen, Belgium; Department of Neurology, UMCG Groningen, Groningen, The Netherlands; kUniversity Hospital Essen, Essen, Germany
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Increasing age is associated with poor outcome after stroke. The Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke (SENTIS) trial explored the augmentation of collateral circulation to the ischemic penumbra as a novel approach to stroke treatment. The aim of this post hoc analysis was to examine the effect of age on outcomes in the SENTIS trial. Methods: Using data from the randomized controlled SENTIS trial, we explored outcomes of cerebral blood flow augmentation using the NeuroFlo™ device in patients categorized by age strata at 70 and 80 years. We evaluated outcomes of overall serious adverse event (SAE) and intracerebral hemorrhage (ICH) rates, freedom from all-cause and stroke-related mortality, and independent functional outcome as defined by the modified Rankin Scale score (mRS ≤2). Results: The SENTIS as-treated cohort included 251 patients ≥70 years and 107 patients ≥80 years. Elderly SENTIS patients included a higher percentage of women and Caucasians than the younger group. Patients in the older group more frequently had vascular risk factors including hypertension, previous stroke, transient ischemic attacks and atrial fibrillation. However, baseline risk-factor profile, stroke severity, and time to randomization did not differ between the treated and nontreated elderly patients. The older patients treated with NeuroFlo had significantly higher chances for survival and for obtaining an independent functional state (mRS ≤2) compared with those who were not treated. Rates of SAEs and ICHs did not differ between the treatment groups. Conclusions: NeuroFlo treatment is safe and results in better outcomes for elderly patients. This may be the result of recruitment and support of already existing collateral systems in these patients.
© 2012 S. Karger AG, Basel
- Hammer M, Jovin T, Wahr JA, Heiss WD: Partial occlusion of the descending aorta increases cerebral blood flow in a nonstroke porcine model. Cerebrovasc Dis 2009;28:406–410.
- Lylyk P, Vila JF, Miranda C, Ferrario A, Romero R, Cohen JE: Partial aortic obstruction improves cerebral perfusion and clinical symptoms in patients with symptomatic vasospasm. Neurol Res 2005;27(suppl 1):S129–135.
- Emery DJ, Schellinger PD, Selchen D, Douen AG, Chan R, Shuaib A, Butcher KS: Safety and feasibility of collateral blood flow augmentation after intravenous thrombolysis. Stroke 2011;42:1135–1137.
Hammer MD, Schwamm L, Starkman S, Schellinger PD, Jovin T, Nogueira R, Burgin WS, Sen S, Diener HC, Watson T, Michel P, Shuaib A, Dillon W, Liebeskind DS: Safety and feasibility of NeuroFlo use in eight- to 24 h ischemic stroke patients. Int J Stroke, E-pub ahead of print.
- Shuaib A, Bornstein NM, Diener HC, Dillon W, Fisher M, Hammer MD, Molina CA, Rutledge JN, Saver JL, Schellinger PD, Shownkeen H, SENTIS Trial Investigators: Partial aortic occlusion for cerebral perfusion augmentation: Safety and Efficacy of NeuroFlo in Acute Ischemic Stroke Trial. Stroke 2011;42:1680–1690.
- Liebeskind DS: Aortic occlusion for cerebral ischemia: from theory to practice. Curr Cardiol Rep 2008;10:31–36.
- Bhatnagar P, Sinha D, Parker RA, Guyler P, O’Brien A: Intravenous thrombolysis in acute ischaemic stroke: a systematic review and meta-analysis to aid decision making in patients over 80 years of age. J Neurol Neurosurg Psychiatry 2011;82:712–717.
- Engelter ST, Reichhart M, Sekoranja L, Georgiadis D, Baumann A, Weder B, Müller F, Lüthy R, Arnold M, Michel P, Mattle HP, Tettenborn B, Hungerbühler HJ, Baumgartner RW, Sztajzel R, Bogousslavsky J, Lyrer PA: Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis. Neurology 2005;65:1795–1798.
- Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333:1581–1587.
- Wahlgren N, Ahmed N, Eriksson N, Aichner F, Bluhmki E, Dávalos A, Erilä T, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Köhrmann M, Larrue V, Lees KR, Machnig T, Roine RO, Toni D, Vanhooren G, Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy Investigators: Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST). Stroke 2008;39:3316–3322.
- Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB, American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Executive summary: heart disease and stroke statistics – 2012 update: a report from the American Heart Association. Circulation 2012;125:188–197.
- Arkadir D, Eichel R, Gomori JM, Ben Hur T, Cohen JE, Leker RR: Multimodal reperfusion therapy for large hemispheric infarcts in octogenarians: is good outcome a realistic goal? AJNR Am J Neuroradiol 2012;33:1167–1169.
- Qureshi AI, Suri MF, Georgiadis AL, Vazquez G, Janjua NA: Intra-arterial recanalization techniques for patients 80 years or older with acute ischemic stroke: pooled analysis from 4 prospective studies. AJNR Am J Neuroradiol 2009;30:1184–1189.
- Berrouschot J, Rother J, Glahn J, Kucinski T, Fiehler J, Thomalla G: Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (> or = 80 years) stroke patients. Stroke 2005;36:2421–2425.
- Mishra NK, Diener HC, Lyden PD, Bluhmki E, Lees KR: Influence of age on outcome from thrombolysis in acute stroke: a controlled comparison in patients from the Virtual International Stroke Trials Archive (VISTA). Stroke 2011;41:2840–2848.
- Nathoe HM, Koerselman J, Buskens E, van Dijk D, Stella PR, Plokker TH, Doevendans PA, Grobbee DE, de Jaegere PP, Octopus Study Group: Determinants and prognostic significance of collaterals in patients undergoing coronary revascularization. Am J Cardiol 2006;98:31–35.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.